Exp Clin Endocrinol Diabetes 1998; 106(5): 365-368
DOI: 10.1055/s-0029-1211999
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Transsexualism and osteoporosis

K. Schlatterer1 , D. P. Auer2 , A. Yassouridis3 , K. von Werder4 , G. K. Stalla1
  • 1Dept. of Endocrinology, Max Planck Institute of Psychiatry, Munich, Germany
  • 2Dept. of NMR, Max Planck Institute of Psychiatry, Munich, Germany
  • 3Dept. of Statistics, Max Planck Institute of Psychiatry, Munich, Germany
  • 4Schloßpark Clinic, Humboldt University Berlin, Germany
Further Information

Publication History

Publication Date:
14 July 2009 (online)


The aim of this study was to investigate whether and to what extent our regime of cross-gender hormone replacement therapy might influence osteoporosis development in transsexual patients. We found that after long-term therapy the bone densities of our cross-gender hormone-treated transsexual groups (10 male-to-female and 10 female-to-male) did not show significant differences compared to those of the corresponding biological sex. Moreover, the bone-density during therapy pointed out very little variability and that independent of the gender-alteration (trans-sexuality-direction) and the age of the transsexuals. Our results indicate that for transsexual patients treated with cross-gender hormone replacement therapy the risk of developing osteoporosis is low.